22 related articles for article (PubMed ID: 2009081)
1. Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice.
Tolledo C; Stocco MR; Miksys S; Gonzalez FJ; Tyndale RF
Mol Neurobiol; 2020 Jun; 57(6):2509-2520. PubMed ID: 32189192
[TBL] [Abstract][Full Text] [Related]
2. Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: Effects on activity and drug responses.
Tolledo EC; Miksys S; Gonzalez FJ; Tyndale RF
Br J Pharmacol; 2020 Feb; 177(3):701-712. PubMed ID: 31648367
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol.
Rowland K; Yeo WW; Ellis SW; Chadwick IG; Haq I; Lennard MS; Jackson PR; Ramsay LE; Tucker GT
Br J Clin Pharmacol; 1994 Jul; 38(1):9-14. PubMed ID: 7946944
[TBL] [Abstract][Full Text] [Related]
4. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.
Yoshimoto K; Echizen H; Chiba K; Tani M; Ishizaki T
Br J Clin Pharmacol; 1995 Apr; 39(4):421-31. PubMed ID: 7640150
[TBL] [Abstract][Full Text] [Related]
5. Activation of propranolol and irreversible binding to rat liver microsomes: strain differences and effects of inhibitors.
Masubuchi Y; Narimatsu S; Suzuki T
Biochem Pharmacol; 1992 Feb; 43(3):635-7. PubMed ID: 1540217
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
Masubuchi Y; Hosokawa S; Horie T; Suzuki T; Ohmori S; Kitada M; Narimatsu S
Drug Metab Dispos; 1994; 22(6):909-15. PubMed ID: 7895609
[TBL] [Abstract][Full Text] [Related]
7. A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.
Inaba T; Nakano M; Otton SV; Mahon WA; Kalow W
Can J Physiol Pharmacol; 1984 Jul; 62(7):860-2. PubMed ID: 6498616
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes.
Suzuki T; Fujita S; Narimatsu S; Masubuchi Y; Tachibana M; Ohta S; Hirobe M
FASEB J; 1992 Jan; 6(2):771-6. PubMed ID: 1537468
[TBL] [Abstract][Full Text] [Related]
9. Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes.
Masubuchi Y; Iwasa T; Hosokawa S; Suzuki T; Horie T; Imaoka S; Funae Y; Narimatsu S
J Pharmacol Exp Ther; 1997 Sep; 282(3):1435-41. PubMed ID: 9316857
[TBL] [Abstract][Full Text] [Related]
10. Impairment of debrisoquine 4-hydroxylase and related monooxygenase activities in the rat following treatment with propranolol.
Masubuchi Y; Fujita S; Chiba M; Kagimoto N; Umeda S; Suzuki T
Biochem Pharmacol; 1991 Mar 15-Apr 1; 41(6-7):861-5. PubMed ID: 2009081
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of fungal sterol synthesis: squalene-epoxidation and C-14-demethylation.
Berg D; Plempel M
J Enzyme Inhib; 1989; 3(1):1-11. PubMed ID: 2487319
[No Abstract] [Full Text] [Related]
12. Cytochrome P-450 as a target for therapeutic inhibitors.
Mason JI
Biochem Soc Trans; 1993 Nov; 21(4):1057-60. PubMed ID: 8131897
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
